Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07606625 · ClinicalTrials.gov registry record · Phase 4
Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment
A Phase 4 study, sponsored by University of California, Berkeley.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT07606625: Recruiting Phase 4 study, sponsored by University of California, Berkeley.
NCT07606625 is a Phase 4 study that is actively recruiting participants, run by University of California, Berkeley. The registered enrollment target is 65 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07606625, a Phase 4 study, is actively recruiting participants, sponsored by University of California, Berkeley.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).
Primary Outcome
Change from baseline in the thickness of the tear lipid layer in microns measured using the EASYTEARView+ Dacryscope. An increase in tear lipid layer thickness is considered a positive treatment effect
Interventions
- DRUG Varenicline 0.03Mg/Spray Nasal Soln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2026-03-06 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT07606625 shows while recruiting
NCT07606625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Varenicline 0.03Mg/Spray Nasal Soln is the first listed.
NCT07606625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07606625 about?
NCT07606625 is a clinical study titled "Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment". The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).
What is the current status of trial NCT07606625?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2026-03-06. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT07606625?
The interventions under investigation include: Varenicline 0.03Mg/Spray Nasal Soln (DRUG).
Who is sponsoring clinical trial NCT07606625?
This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07606625's enrollment target sits among peer trials
65 1091st of 2000 higher than 903 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI